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Over recent decades, increased longevity has not been paralleled by extended healthspan, resulting in 
more years spent with multiple diseases in older age. As such, interventions to improve healthspan are 
urgently required. Zoledronate is a nitrogen containing bisphosphonate, which inhibits the farnesyl 
pyrophosphate synthase (FPPS) enzyme, central to the mevalonate pathway. It is already used 
clinically to prevent fractures in osteoporotic patients, who have been reported to derive unexpected 
and unexplained survival benefits. Using Drosophila as a model we determined the effects of 
Zoledronate on lifespan, parameters of healthspan (climbing ability and intestinal dysplasia) and the 
ability to confer resistance to oxidative stress using a combination of genetically manipulated 
Drosophila strains and Western blotting. Our study shows that Zoledronate extended lifespan, 
improved climbing activity and reduced intestinal epithelial dysplasia and permeability with age. 
Mechanistic studies showed that Zoledronate conferred resistance to oxidative stress and reduced 
accumulation of X-ray-induced DNA damage via inhibition of FPPS. Moreover, Zoledronate was 
associated with inhibition of pAKT in the mTOR pathway downstream of the mevalonate pathway and 
required dFOXO for its action, both molecules associated with increased longevity. Taken together, 
our work indicates that Zoledronate, a drug already widely used to prevent osteoporosis and dosed 
only once a year, modulates important mechanisms of ageing. Its repurposing holds great promise as a 
treatment to improve healthspan. 
 




















It has been estimated that by 2050, Europe, North America, and eight countries across the other 
continents will have more than 30% of their population over the age of 60(1). However, this increase 
in life expectancy has not translated into extended healthspan(2). More than 60% of those over the age 
of 65 suffer from multimorbidities – defined as the co-existence of multiple chronic health 
conditions(3). These multimorbidities impose quality-of-life and care management challenges 
associated with treating multiple conditions individually and are frequently associated with increased 
costs, reduced efficacy and increased likelihood of adverse events due to polypharmacy(4). Targeting 
pathways underpinning central mechanisms of ageing, which are common to multiple disorders offers 
new opportunities to treat multimorbidity and overcome these problems.  
 
Zoledronate (Zol) is a nitrogen containing-bisphosphonate used for the treatment of skeletal disorders, 
including osteoporosis. It inhibits the mevalonate pathway through inhibition of the enzyme farnesyl 
pyrophosphate synthase (FPPS)(5) and thereby inhibits bone resorption by inhibition of osteoclast 
activity. Due to its high affinity binding to hydroxyapatite crystal mineralisation, Zol is strongly 
enriched in bone and released following bone breakdown conferring long lasting activity(6). In 
clinical practice, Zol is administered by intravenous infusion once a year in post-menopausal women 
to prevent fractures(7, 8). Recently, retrospective analysis of several clinical trials showed that 
patients treated with Zol had a significant decrease in mortality rates(9). In addition, among patients 
admitted to intensive care units, those previously treated with Zol had increase survival despite overall 
higher level of multimorbidities and older age(10). It is unknown whether other mechanisms 
independent of bone protection may be involved in the Zol-dependent extension of survival. 
 
The mevalonate pathway is an important metabolic pathway responsible for the production of 
cholesterol and protein prenylation. One key group of isoprenylated proteins are small GTPases(11), 


















cellular morphology, integrin function and longevity-associated pathways such as mTOR(12). In this 
study we examined whether Zol is able to extend lifespan and healthspan independent of its effect on 
bone using Drosophila, a model widely used for ageing studies. While retaining evolutionarily 
conserved components of both the mevalonate and mTOR pathways, Drosophila does not feature the 
bone-like mineralisation present in mammalian models(13). This approach allows us to exclude 
mechanisms, which have been hypothesized to explain Zol-mediated increases in human survival. 
These include the bone acting as a regulator of other tissues’ homeostasis(10) through the release of 
hormones such as osteocalcin a regulator of glucose homeostasis(14) . In doing so, our approach 
allows osteo-protective and gero-protective activities to be dissected in vivo. Our results uncovered a 
previously unrecognised role of Zol extending both lifespan and healthspan and improving survival in 
the presence of oxidative stress. The extension in survival by Zol is associated with a reduction in 
pAKT expression and requires dFOXO signalling, a conserved pathway well known for its positive 









) stock has been maintained in large population cages with overlapping 






















 (ref(17)) were obtained from the Bloomington Drosophila Stock 
Centre. w; Su(H)-lacZ, esg-Gal4,UAS-GFP/CyO expresses GFP in intestinal stem cells and 




 is a 
recombinant between GMR-Gal4 (ref(19)) and GD30033, an in vivo hairpin loop RNAi 


















All flies were maintained in a 12:12h light-dark cycle on standard yeast, molasses, cornmeal, 
agar food at 18°C or 25°C. Drug-containing food was prepared using freshly cooked molten 
fly food cooled to 60°C. Zol (kindly provided by Hal Hebetino, University of Rochester), 
GGOH (Sigma Aldrich, Dorset, U.K.) and FOH (Sigma Aldrich, Dorset, U.K.) or carrier(s) 
were added, mixed thoroughly and immediately poured into standard vials and bottles so as 
to minimize exposure of drug to high temperatures. The continued activity of Zol following 
brief exposure to this temperature was confirmed molecularly (data not shown). Drug food 
was stored at 4°C until use for a maximum of 3 weeks. 
 
For lifespan experiments overnight embryo collections from approximately 200 adult flies 
were collected on apple juice agar plates, washed with water and 32µl of embryos transferred 
into food bottles. Flies that subsequently ecclosed within the first 24hrs of the first to emerge 
were discarded with those subsequently ecclosing over an 16-20 hour overnight collection 
window being used for experiments. These later flies were transferred into new food bottles 
without the use of CO2 and incubated for 3-4 days. Flies were then sorted by gender and 
counted while minimizing CO2 exposure. 
 
Longevity Assay and H2O2 Survival Assays 
For longevity assays, 20 gender matched flies were maintained in vials of food and 
transferred into new vials every 2-3 days. At every transfer numbers of dead or censored flies 
were recorded. Unless specifically specified 100 flies were analysed for each experimental 
with three independent experimental replicates. To test survival in presence of hydrogen 
peroxide, adult flies of the appropriate genotype and pre-treatment were first starved in vials 
containing 1% agar for 3 hours and then transferred to standard food containing 5% H2O2 and 


















2 hours for the next 48 hours. If 100% mortality was not reached by that point, scoring was 
continued every 12 hours. 
 
Rapid iterative negative geotaxis (RING) assays 
For rapid iterative negative geotaxis (RING) assay flies we kept in groups of ~150. The day 
before an experiment, flies were sorted into groups of 20 and transferred into separate vials 
following brief CO2 anaesthesia. Flies were then transferred into 25ml strippette (Fisher 
Scientific) and after 1 minute, the strippette was tapped to knock flies to the bottom and 
initiate the negative geotaxic response. After 15 seconds a photograph was taken and the 
position of each fly, and hence the distance climbed, was recorded. Twenty flies were 
assessed from each condition with each experiment repeated 3 times. Flies that climbed 
above 10cm were classified as „high climbers‟. 
 
Gut barrier integrity and food uptake assays 
For gut barrier integrity assays Drosophila food containing 2.5% (w/v) erioglaucine disodium 
salt (Sigma Aldrich) and drugs (as appropriate) was fed to flies for 9 hours. For gut integrity 
assays flies were scored for uniform blue coloration beyond the GI tract („Smurf-ness‟).  
Food uptake assays were undertaken as described in (21) using food containing 1% (w/v) 
erioglaucine disodium salt and 11.7µM Zol as appropriate. Ten adult flies between 8-11d old 
were placed in vials for 22h and allowed to feed ad libitum at 25°C. Flies were frozen and 
then dissociated in dH2O before centrifugation to pellet debris and extract colour from 
internalised food. In addition, colour present in faecal matter deposited on the walls of the 
vial was recovered by washing with dH2O. Colour, and hence quantity of food consumed was 
calculated on the basis of OD 630nm measurements and reference to a standard curve of dye 


















of 10 flies were tested for each condition and gender and tested by one-way ANOVA. Final 
values are expressed as µg food per fly per day (correcting for the 22h sampling period).   
  
DNA damage assay  




 adults outcrossed to OreR were 
allowed to develop for 96 hours at 25°C. These heterozygous third instar larvae were then 
irradiated with 200Gy using a Torrex Cabinet X-ray system (Faxitron X-ray, Arizona, USA) 




Drosophila midgut analysis  
Midguts from Su(H)-lacZ; esg-Gal4,UAS-GFP/CyO female adults were dissected in cold 
PBS and fixed in PBS+4% formaldehyde and blocked in PBST (PBS, 0.1% Triton X-100 and 
1% BSA). Antibodies included Chicken anti-GFP 1:4000 (Abcam, Cambridge, UK) and anti-
Phospho-histone H3 1:100 (New England Biolabs, Ipswich, USA) and secondary antibodies 
AlexaFluor
TM
 488 goat anti-chicken and AlexaFluor
TM
 594 goat anti-rabbit IgG (Life 
Technologies, Oregon, USA) were used. Stained guts were mounted with Fluoroshield
TM
 
with DAPI (Sigma Aldrich) and Grace Bio-Labs SecureSeal™ imaging spacers. Samples 
were imaged using Perkin Elmer Spinning Disk confocal microscope with a 40X objective. 




















Protein extraction and western blot 
Thirty flies of the appropriate genotype were snap frozen in liquid N2 and crushed using an 
Eppendorf pestle in 200µl ice-old lysis buffer (50mM Tris HCl pH 7.4, 250mM NaCl, 5mM 
EDTA and 0.003% Triton X-100) with protease inhibitor (cOmplete Mini, EDTA-free, 
ROCHE, Sussex, UK). After 30mins incubation at 4°C extracts were centrifuged at 
13,000rpm, 4°C for 30mins and supernatants stored at -20°C. 
 
Proteins (40-60µg) were electrophoresed through 4–15% Mini-PROTEAN® TGX™ Precast 
Protein Gels (Bio-Rad, Hertfordshire, UK) and transferred onto polyvinylidene difluoride 
(PVDF) membrane (Immobilon-P Membrane, Millipore, Hertfordshire, UK) using standard 
techniques. Primary antibodies used were anti-pAKT 1:500, anti-AKT 1:500, anti-tubulin 
1:1000 (Cell Signaling Technology, Denver, Massachusetts). HRP conjugated secondary 
antibodies were used at 1:10,000 and visualised using ECL (GE Healthcare, 
Buckinghamshire, UK), high performance chemiluminescence film (Amersham Hyperfilm 




Statistical analysis was performed on GraphPad Prism 7. For single comparisons data were 
analysed using non-parametric unpaired Student‟s t-test. For multiple comparisons, ordinary 
one-way analysis of variance (ANOVA) was used followed by Sidak‟s multiple comparison 
post-hoc tests. For the analysis of RING assay Two Way ANOVA was used followed by 


















different ages. Survival data was analysed using Log-rank (Mantel-Cox) test to identify 
significant differences in organism survival between treatment groups. For the analysis of the 
Smurf assay Chi-squared test was used. All data is expressed as mean ± standard deviation 
(SD). A difference was stated to be statistically significant if the p value was <0.05 (*p<0.05; 
**p<0.01; ***p<0.001; ****p<0.0001).  
 
RESULTS 
Zol increases lifespan in Drosophila 
To determine whether Zol might have beneficial effects on the lifespan of Drosophila, both male and 
female w
Dah
 flies were maintained on standard fly food supplemented with 1μM or 10μM Zol from 
day 4 of adult life onwards (Fig. 1 A&B and eFig.1). In multiple experimental replicates, the survival 
of males fed with 1μM Zol was significantly increased compared to the vehicle-treated group (Fig. 1A 
and eFig.1). By contrast, females, showed no significant beneficial effect when treated with Zol at 
1μM throughout their lives and 10μM of Zol had adverse effects on female survival (Fig. 1B).  
 
As Zol modulates the mevalonate pathway through inhibition of FPPS, we next tested the lifespan of 




/+) – two independently generated 
homozygous-lethal loss-of-function alleles containing transposon insertions within the FPPS gene
15
. 
Following at least 7 generations of outcrossing into the w
Dah
 genetic background, both mutant strains 
showed a statistically significant increase in overall survival in males and females compared to w
Dah
 
controls (Fig. 1 C&D and eFig2) suggesting that reduced FPPS activity mediates an extension in 
lifespan.  
 
To limit potential side effects due to long term drug treatment, we next assessed the effects of Zol on 


















eFig.3). This late treatment led to a significant increase in survivorship in both males and females for 
both 1 and 10μM Zol compared to controls (Fig. 1 E&F and eFig.3). This lifespan extension was 
significant for both males and females with 1μM Zol producing average median lifespans increases of 
1.79% (±0.10%) and 11.53% (±2.10%)(N=3) for male and females respectively, while with 10μM 
Zol, survival was increased in males by 4.67% (±1.03%) and females by 16.51% (±4.94%) (N=3). 
Finally, to verify that these results were not influenced by calorific restriction caused by unpalatable 
food we exposed the flies to drug-laced food containing a non-toxic food colorant via which the 
volume of food both present within flies and excreted can be measured. No significant difference in 
food uptake was observed in presence of Zol in either males or females (eFig. 4 n=10/trial, 10 trials 
per condition), excluding the possibility that the life extending effects were the result of caloric 
restriction. 
 
Zol increases healthspan in Drosophila 
To determine whether Zol improved signs of healthspan we next tested its effects in Drosophila by 
assessing their ability to climb and by the presence of signs of intestinal epithelial dysplasia and 
intestinal permeability. Displaying strong negative geotactic responses, climbing activity is a widely 
used assay of Drosophila health and activity(22) and was assessed using the rapid iterative negative 
geotaxis (RING) assay (Fig. 2). We classed as “high climbers” flies able to climb over 10cm in 15 
seconds. As expected, the percentage of high climbers decreased significantly with age in both males 
(Fig. 2 A&C) and females (Fig. 2 B&D). However, a significant improvement in climbing ability was 
observed in both males and females receiving Zol from day 4 of adult life (Fig. 2 A&B) or starting at 
40 days of life (Fig. 2 C&D) when as assessed at 42 and 56 days of age respectively. Two-way 
ANOVA analysis showed that, despite a significant interaction between age and treatment (Fig. 2 for 
details of statistical analysis), no significant effect of Zol was observed at a later time point in any of 
the conditions analysed by post hoc test. These data show there is an overall improvement in climbing 



















As flies age, intestinal barrier dysfunction and epithelial dysplasia develop in female flies, a 
development associated with increased mortality and a development considered to be a good marker 
of healthspan(23). To determine the effects of Zol on epithelial dysplasia we examined intestinal 
morphology at day 7, 42 and 63 of adult life following treatment with vehicle or Zol starting at either 
day 4 or 40 of adult life. Using Su(H)-lacZ; esg-Gal4, UAS-GFP reporters we labeled intestinal stem 
cells and enteroblasts (progenitor cells) on the basis of GFP expression driven by the escargot 
promoter - a marker associated with stemness. Epithelial dysplasia in the Drosophila gut is 
characterised by hyperproliferation, as identified by the G2/M marker phospho-Histone3 (pH3)(24) 
and mis-differentiation of intestinal stem cells(25). As expected, we observed an increase in intestinal 
stem-cell proliferation with age in vehicle treated flies as shown by the significant increase in the 
number of GFP+ / pH3 positive cells with age (Fig. 3 A&B) and an increase in the overall proportion 
of GFP+ cells (Fig. 3 C&D). Both parameters are significantly decreased in female flies treated with 
Zol (Fig. 3 A-D).  
 
One of the key roles played by the intestinal epithelia is to provide an impermeable barrier to the 
exterior environment in which damaged or dying epithelial cells are replaced with new cells generated 
by the ISCs. A loss of barrier function in the intestinal epithelium has been reported with age in both 
flies and humans. To assess intestinal integrity we performed the “Smurf assay”(26) in which blue 
colouring added to regular food is able to cross a compromised epithelium and stain the entire fly 
blue. Consistent with previous findings, the percentage of flies presenting the „Smurf‟ phenotype was 
increased with age and is attenuated by treatment with Zol under the all-life feeding regime (Fig. 3 
E&F).  
 
Taken together, these data suggest that treatment with Zol throughout adult life reduces intestinal 



















Zol increases lifespan of flies exposed to oxidative stress through FOXO 
To elucidate the mechanism of action mediating the beneficial effects of Zol and considering the role 
of GTPases in longevity we hypothesized that resistance to oxidative stress was partly responsible for 
the increased survivorship. Therefore, flies were challenged with food containing 5% H2O2, a 
treatment that reduces absolute lifespan and acts as a source of oxidative stress. Groups of adult, 11-
day old female w
Dah
 flies were subjected to 5% H2O2 at the same time as either Zol or Rapamycin 
used as a positive control(27). We also tested another group of flies pre-treated with Zol for 7 days 
before exposure to 5% H2O2 (Fig. 4A). While the survival of flies treated with Rapamycin increased 
significantly compared to vehicle control, Zol-treatment did not improve survival when administered 
at the same time as the 5% H2O2 (Fig.  4B). By contrast, survival in response to H2O2 was 
significantly increased following pre-treatment with Zol for 7 days (Fig. 4B). To determine whether 
the increase was due to inhibition of FPPS, flies pre-treated with Zol were also treated with the 
downstream metabolites of the mevalonate pathway, Farnesyl farnesol (FOH) and Geranyl geranyol 
(GGOH), which bypass the block in FPPS inhibition. As expected, the survival advantage provided by 
Zol pre-treatment was abrogated in the presence of FOH and GGOH demonstrating that the extension 
in survival is due inhibition of the mevalonate pathway (Fig. 4C). To further support the hypothesis 





/+ heterozygotes outcrossed into a w
Dah
 genetic background were also subjected to 5% H2O2 
and their survival assessed. In these flies, survival was also significantly increased compared to w
Dah
 
controls following exposure to H2O2-induced oxidative stress (Fig. 4D). Taken together these data 
suggest that the Zol confers resistance to oxidative stress and demonstrates that these effects are 
mediated by inhibition of the FPPS enzyme in the mevalonate pathway. 
 
To determine the mechanism of action downstream of the mevalonate pathway, we hypothesized that 


















whether Zol protects Drosophila from oxidative damage through dFOXO, heterozygous dFOXO
 Δ94
/+ 
loss of function mutations(17) and w
Dah
 controls were pre-treated with either Zol at the highest dose 
of 10µM or vehicle control-containing food for 7 days before exposure to food containing 5% H2O2. 
While w
Dah
 pre-treated with Zol showed a significant increase in lifespan, dFOXO
 Δ94
/+ flies treated in 
the same way did not show any beneficial effect (Fig. 4E), suggesting dFOXO is required for Zol 
action on survival.  
 
Given that pAKT is a known regulator of FOXO(28) we next determined levels of pAKT, following 
treatment with Zol and observed a significant decrease (Fig. 4F and eFig. 5). Furthermore, these 
effects were reversed by the addition of FOH and GGOH (Fig. 4 F&G), suggesting that inhibition of 
pAKT is dependent on the mevalonate pathway.  
 
Taken together these data suggest that Zol confers resistance to oxidative damage via inhibition of the 
mevalonate pathway through a mechanism that requires dFOXO for its activity.  
 
 
Zol enhances DNA damage repair in Drosophila upon irradiation  
DNA damage and the resulting mutations induced by ionizing radiation are at least partly caused by 
increased oxidative stress(29). We therefore wanted to determine whether the ability of Zol to protect 
against H2O2-induced oxidative stress would also reduce the frequency of DNA damage induced by 
X-ray irradiation. In order to visualise DNA damage in an in vivo environment, we developed an 
assay in which endogenously expressed mRNA from the wild type white locus is knocked down by an 
in vivo RNAi hairpin-loop expressed within the cells of the future eye. Where knock down is 
successful, white mRNA is destroyed and very little pigment is produced, resulting in pale yellow eye 




















system are mutated, white mRNA is not destroyed and wild type levels of red pigment are produced to 
give a readily recognisable red eye clone (Fig. 5A) in adult Drosophila. In order to assess DNA 
damage levels using this reporter, larvae heterozygous for the GMR-Gal4,UAS-white
RNAi 
reporter were 
raised on food containing either carrier controls, 1μM Zol, 10μM Zol or a combination of 10μM Zol 
and 33μM FOH and 33μM GGOH. Larvae were irradiated 96 hours after hatching using one dose of 
200Gy of X-ray irradiation (Fig. 5C). Strikingly, GMR-Gal4,UAS-white
RNAi
/+ flies contained 
significantly lower frequency of red-marked mutated cells when grown on 1 or 10μM Zol-containing 
food compared to controls. However, when Drosophila were treated with 10μM Zol in combination 
with FOH and GGOH, a partial reversal of this effect was observed (Fig. 5C). These data suggest that 
Zol is also able to protect individuals from the accumulation of mutations, via mechanism(s) that, at 
least in part, depend on the mevalonate pathway. 
 
DISCUSSION 
In this study we show that Zol has properties of a geroprotector, an activity mediated by its inhibition 
of FPPS. We show that Zol extends the lifespan and healthspan of Drosophila in absence of 
mineralised bone-like structures and demonstrate that it confers resistance to oxidative damage via the 
inhibition of FPPS in the mevalonat  pathway. The median extension of lifespan by Zol is in the same 
range of other geroprotectors including rapamycin, with Zol extending the median lifespan of 
females by 14-18% when given from middle age. Rapamycin, one of the most studied 
geroprotectors, which positively impacts on the immune system in older patients by boosting their 
ability to improve flu vaccine responses(30) and also improves several healthspan parameters in 
mice(31), increases lifespan by 9-14% in female mice when fed late in life(32). A similar level of 



















Our results suggest that Zol requires dFOXO for its action and is associated with reduction in the 
levels of pAKT. These in vivo findings are in line with our previous work in human mesenchymal 
stem cells (hMSC) where we have shown that Zol was able to reduce the accumulation of DNA 
damage caused by cellular ageing or irradiation via a mechanism requiring FOXO3a, as well as 
reducing the accumulation of senescent markers p16 and p21 (ref(34)). In addition, Zol was able to 
increase the translocation of pFOXO3a to the nucleus in human mesenchymal stem cells and this 
was reversed by the addition of FOH and GGOH, suggesting an action on the activation of 
FOXO3a(34). Molecules such as Rheb and Ras are small GTPases prenylated via the mevalonate 
pathway and upstream of TORC1 and TORC2 and therefore are likely candidates to mediate the 
regulation of pAKT and FOXO by Zol(35, 36). FOXO is a key player in ageing and has been shown to 
regulate several of its hallmarks including DNA damage, senescence, changes in mitochondrial 
function and mutation rates(37). Whilst Drosophila have a single FOXO gene (dFOXO), the human 
genome is more complex and encodes four different FOXO proteins, with polymorphisms in FOXO3a 
having been associated with exceptional longevity(38, 39). In addition, FOXO3a activity has been 
shown to reduce the effects of reactive oxygen species (ROS) production in multiple ways. For 
example, its expression improves the fidelity of DNA damage repair by arresting the cell cycle to 
allow the repair of damaged DNA(40, 41). In addition, FOXO3a activation results in the repression of 
a large number of nuclear-encoded genes with mitochondrial function(42). As most intrinsic ROS are 
produced by the respiratory complexes located in the inner mitochondrial membrane, these changes in 
mitochondrial activity may directly influence the levels of ROS production in vivo. More work is 
required to understand in detail which of these mechanisms and molecular pathways Zol modulates 
via FOXO. In addition, it will be important to determine which of the many small GTPases 
modulated by the mevalonate pathway are responsible for FOXO activity. A detailed analysis of each 
individual tissue in a mammalian system is also required as there are important differences in 



















A similar molecular mechanism mediating extension of lifespan has been described following 
administration of statins in C. elegans. Statins inhibits HMG-Co-A reductase in the mevalonate 
pathway and extends lifespan via DAF16/FOXO3a(44).   However, statins are administered daily as 
opposed to Zol which is given once a year in patients affected by osteoporosis. This can be an 
advantage in terms of cost-effectiveness, especially when considering preventive interventions.  
 
One observation we made is that the effects of Zol varied depending on time of administration, dose 
and sex differences that may be partly due to differences in drug uptake by males and females. In 
females, egg production requires higher levels of nutritional input than required by males, resulting 
potentially in increased food consumption and therefore increased drug uptake with consequent signs 
of toxicity(45). By contrast, in the FPPS mutants, where the action of the enzyme is disrupted 
independently of drug uptake, similar lifespan extension is observed in both sexes suggesting that the 
effect of mevalonate pathway inhibition on lifespan is unlikely to be sexually dimorphic. However, 
further work is required to understand this aspect of the work. 
 
In addition to differences in lifespan extension, it is intriguing to note that indicators of improved 
health such as climbing ability and intestinal dysplasia occur even at high doses of Zol that reduce 
absolute lifespan (compare Fig. 1B 10µM with Fig. 3A, 63day 10µM), demonstrating that drug 
treatment is able to increase healthspan independently of absolute lifespan. This observation is in line 
with the finding of others which shows that healthspan and lifespan are not necessarily related(46). 
For example, Nicotinamide has recently been shown to improve aspects of healthspan but not 
lifespan(47). This disconnect between healthspan and lifespan may indicate that organisms can cope 
with the accumulation of a certain number of defects which are sufficient to negatively affect 
healthspan but which do not lead directly to death. Being able to reduce these healthspan-associated 
deficits is of particular interest from a translational perspective as they contribute to morbidity and 



















Another notable aspect of Zol treatment in Drosophila is the improvement in lifespan and healthspan 
measures following treatment that begins only in middle age (Fig. 1 E&F). It is unclear why the 
effects are more prominent when the treatment starts at middle age, particularly in females. The 
treatment profile observed in these flies mirrors that of women affected by osteoporosis who also 
generally begin Zol treatment post-menopausally. In both Drosophila and humans, the effect of Zol 
on survival is only detectable sometime after initial treatment(48). On average, it takes 16 months 
before an improvement in survival is observed in postmenopausal women(48) and approximately 14 
days in Drosophila (Fig. 1F). The reasons for this delayed phenotypic response are unclear but may 
reflect an ability by Zol to improve biological processes only when they are mildly dysregulated. 
However, when those mechanisms are either working at healthy levels or when their dysregulation 
exceeds a compensatory threshold then Zol treatment is either not needed or no longer sufficient to 
maintain function. Consistent with this model, Zol did not have any effect on climbing activity in 
geriatric flies at 70 days of age – when no activity was detected in any of the populations tested. It is 
possible that a similar process may also explain why a Zol-mediated extension of lifespan was not 
observed in Zmpste24
-/-
 mice. In this model of Hutchinson-Guilford progeria syndrome Zol alone does 
not modify premature ageing while combined treatment with both Zol and statins (which inhibit the 
same pathway) is able to extend lifespan(49). 
 
While evidence collected to date suggests that the effects of Zol on lifespan and healthspan in humans 
may be limited, it should be noted that the effects observed follow treatment with just a single yearly 
dose. None-the-less, retrospective analysis of patients taking Zol has not only shown a marked 
increase in survival but also a reduction in the frequency of death by pneumonia and cardiovascular 
events, suggesting broader effects unrelated to the musculoskeletal system(9). In addition, patients 
treated with Zol and admitted to hospital for intensive / critical care for a condition not related to 


















Furthermore, the patients previously treated with Zol required 30% shorter in-patient care despite 
being older than the control group and having higher comorbidity index(10).  
 
Older people with frailty and multimorbidity have a reduced ability to respond to adverse events and 
often lose independence following major health-related incidents. Such events have significant 
consequences for follow up health and social care costs(50, 51). Indeed, there has been an increase of 
18% in the number of emergency admissions of older patients between 2010/11 and 2014/15 in the 
UK with those patients over the age of 65 now accounting for 62% of total bed days spent in hospital. 
Considering average cost for a patient to stay in an NHS ward is up to £400 per day, the financial and 
societal benefits of improving resilience in older people and reducing length of hospital stay are 
huge(51). 
 
In conclusion we have shown that inhibition of FPPS by Zol modulates mechanisms of 
ageing to extend lifespan and healthspan in vivo – an effect that is independent of its effects 
on bone. These findings are in line with the unexplained improved survival rates that have 
been reported recently for patients being treated with Zol – findings that highlight the 
substantial benefit Zol can potentially provide with only a single yearly treatment. Studies in 
mammalian models are now required to understand the effects of Zol on specific tissues, to 
define which of the FOXO-regulated mechanisms are at play and whether an infrequent 
administration of Zol is the best approach to elicit the strongest beneficial effects.  Given that 
Zol is off-patent, available at low cost and displays a well understood safety profile featuring 
minimal side effects, we suggest that repurposing studies seeking to widen the use of Zol are 
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Fig. 1 Administration of Zol affects lifespan of flies 
Percentage survival of (A) male and (B) female w
Dah
 flies fed with food in presence or absence of Zol 
(1 or 10μM) throughout their lives; percentage survival of (C) male and (D) female heterozygote 
FPPS mutant flies and w
Dah
 fed with standard Drosophila food; percentage survival of (G) male and 
(F) female w
Dah
 flies fed with food in presence or absence of Zol (1 or 10μM) from 40 days of age. 
Average of 3 experiments with 100 flies/group/experiment. Log-rank (Mantel-Cox) test in Graphpad 
Prism used to statistically analyse the survival curves, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P 
≤ 0.0001. All experiments were repeated 3 times. 
 
Fig. 2 Flies fed with Zol shows a significant increase in climbing ability at middle age. 
Lifelong treatment with Zol: (A) Percentage of male flies climbed above 10cm (high climbers) within 
15 seconds. (B) Percentage of female flies climbed above 10cm (high climbers) within 15 seconds. 
Flies treated with Zol from midlife: (C) Percentage of male flies climbed above 10cm (high climbers) 
within 15 seconds. (D) Percentage of female flies climbed above 10cm (high climbers) within 15 
seconds. Data were analysed by Two-Way ANOVA and Dunnet‟s multiple comparison test. * P ≤ 
0.05, ** P ≤ 0.01, *** P ≤ 0.001 **** p≤0.0001 
 
Fig. 3 Treatment with Zol reduces epithelial dysplasia and intestinal permeability in Drosophila 
(A-B) Quantification of pH3+ cell in the intestine of Drosophila. Flies were treated with or 1 or 
without 10μM of Zol from 4 days of age (A) or 40 days of age (B). At least 7 midguts were assessed 
per condition and per time point. (C-D) Quantification of %GFP
+
 cells (normalised to DAPI) in the 


















(D). (E-F) Percentage of flies Smurf positive following treatment with or without 1 or 10μM of Zol 
starting from 4 days of age (E) or 40 days of age (F) (n>65 per condition per timepoint). Data were 
analysed with one-way ANOVA and Sidak‟s post-hoc test (number of PH3+ cells and %GFP
+
 cells) 
and Chi square test for the analysis of the smurf assay.  *p<0.05 , **p<0.01, ***p<0.001, 
****p<0.0001 
 
Fig. 4 Zol increases lifespan of flies under oxidative stress through FOXO 
(A) A schematic representation of the experimental design. (B) Survivorship of female w
Dah
 flies fed 
on food containing 5% H2O2. The flies were treated with 5% H2O2 in combination with PBS (vehicle) 
or 10μM Zol or 200μM rapamycin (Rap) both given at the same time than H2O2. Two groups of flies 
were pretreated for 7-days with 10μM Zol (d4) or PBS (d4) as vehicle before addition of H2O2 (C) 
Survivorship of female w
Dah
 flies fed with 5% H2O2. The flies were pre-treated PBS+EtOH 
(Vehicles), 10μM Zol, or 10μM Zol in combination with 330μM FOH & 330μM GGOH. (D) 




/+ fed with 5% H2O2. 
w
Dah
 flies either pre-treated PBS or 10μM Zol, were used as control (E) Survivorship of female 
dFOXO 
Δ94/+
 flies treated with 5% H2O2. w
Dah
 flies either pre-treated with 10μM Zol or PBS (vehicle) 
were used as control. For all survival tests, 100 flies were used in each treatment group per test, 
experiments were repeated 3 times with different cohorts of flies. (F) A representative example of 
AKT and pAKT expression in whole flies fed with Zol (100μM) for 10 days, in presence or absence 
of FOH (330μM), GGOH (330μM). PBS and ethanol (EtOH) were used as vehicle control. (G) 
Quantification of expression level of pAKT normalised to tubulin in presence or absence of Zol 




















Fig. 5 Zol enhances DNA damage repair in Drosophila upon irradiation 
(A) A representative image of an eye from a w
+
; GMR-Gal4, UAS-white RNAi fly (left) and one 
containing a clone of cells in the eye in which DNA damage has led to the production of red pigment 
(right). (B) Time line of experiment. (C) Percentage of eyes with red colonies upon 200Gy irradiation 
in homozygous w+; GMR-Gal4,UAS-white RNAi flies when treated with PBS (control), 1μM Zol, 
10μM Zol, or 10μM Zol with 330μM FOH and GGOH. Data analysed by one way-ANOVA and 
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